QSAR studies of quinidine inhibition of CYP2D6

被引：0
|
作者：
Hutzler, JM [1 ]
Wienkers, LC [1 ]
机构：
[1] Pharmacia Corp, Global Drug Metab, Kalamazoo, MI 49007 USA
来源：
DRUG METABOLISM REVIEWS | 2002年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
343
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [41] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [42] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
  • [43] Influence of CYP3A4 and CYP2D6 inhibition on fesoterodine treatment
    Sachse, R
    Cawello, W
    Horstmann, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1186 - 1186
  • [44] QUINIDINE INHIBITION OF DEBRISOQUINE S(+)-4-HYDROXYLATIONS AND 7-HYDROXYLATIONS IN CHINESE OF DIFFERENT CYP2D6 GENOTYPES
    BERTILSSON, L
    MEESE, CO
    YUE, QY
    DAHL, ML
    INGELMANSUNDBERG, M
    JOHANSSON, I
    SAWE, J
    EICHELBAUM, M
    PHARMACOGENETICS, 1993, 3 (02): : 94 - 100
  • [45] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [46] Pharmacokinetics of Oxycodone in Extensive and Poor Metabolizers of CYP2D6 during Cotreatment with Placebo or Quinidine
    Sirhan-Daneau, Andrea
    Michaud, Veronique
    St-Onge, Maude
    Turgeon, Jacques
    DRUG METABOLISM REVIEWS, 2009, 41 : 81 - 82
  • [47] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [48] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [49] CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene
    Skierka, Jennifer M.
    Walker, Denise L.
    Peterson, Sandra E.
    O'Kane, Dennis J.
    Black, John Logan, III
    PHARMACOGENOMICS, 2012, 13 (08) : 951 - 954
  • [50] Codeine abuse liability is modified by CYP2D6 inhibition.
    Romach, MK
    Kathiramalainathan, K
    Kaplan, HL
    Busto, UE
    Tyndale, RF
    Sellers, EM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI107 - PI107
12345